Exicure, Inc.

NasdaqCM:XCUR 주식 보고서

시가총액: US$5.8m

Exicure 과거 수익 실적

과거 기준 확인 0/6

Exicure has been growing earnings at an average annual rate of 14.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 12.5% per year.

주요 정보

14.9%

수익 성장률

29.8%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률12.5%
자기자본 수익률-506.6%
순이익-1,634.4%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Aug 25
Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Mar 10
Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

수익 및 비용 분석

Exicure 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqCM:XCUR 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 241-860
31 Mar 241-13110
31 Dec 230-17130
30 Sep 23223130
30 Jun 23243130
31 Mar 23261110
31 Dec 2229-3110
30 Sep 229-35130
30 Jun 223-53130
31 Mar 221-60130
31 Dec 210-64130
30 Sep 21-2-63120
30 Jun 214-48110
31 Mar 218-38100
31 Dec 2017-25100
30 Sep 2017-2290
30 Jun 2015-1990
31 Mar 2010-2090
31 Dec 191-2690
30 Sep 191-2180
30 Jun 191-2180
31 Mar 190-2280
31 Dec 180-2280
30 Sep 182-2180
30 Jun 185-1880
31 Mar 187-1480
31 Dec 1710-1170
30 Sep 178-1360
30 Jun 176-1550
31 Mar 173-1640
31 Dec 161-1740
31 Dec 152-650

양질의 수익: XCUR is currently unprofitable.

이익 마진 증가: XCUR is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: XCUR is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.

성장 가속화: Unable to compare XCUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: XCUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


자기자본 수익률

높은 ROE: XCUR has a negative Return on Equity (-506.63%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기